Beyond Guam: The cyanobacteria/BMAA hypothesis of the cause of ALS and other neurodegenerative diseases

Reference

• Tandan R, Bradley WG. Amyotrophic Lateral Sclerosis, Part I: Clinical features, pathology and ethical issues in management. Ann Neurol. 1985a; 18 3: 271–280.
   PubMedGoogle Scholar
• Tandan R, Bradley WG. Amyotrophic Lateral Sclerosis, Part II: Etiopathogenesis. Ann Neurol. 1985b; 18 4: 419–431.
   PubMedGoogle Scholar
• Rowland LP. Six important themes in amyotrophic lateral sclerosis (ALS) research, 1999. J Neurol Sci. 2000; 180:2–6.
   PubMedGoogle Scholar
• Bradley WG. Collaborative National ALS Study Group. Patient orientated research and clinical trials. J Neurol Sci. 2006; 242:71–4.
   PubMedGoogle Scholar
• Murray B, Mitsumoto H. Disorders of Upper and Lower Motor Neurons. In: Bradley WG, Daroff RB, Fenichel GM, Jankovic J. Neurology in Clinical Practice, 5th Butterworth, MA. 2008: 2183–220.
   Google Scholar
• Kuzuhara S. Revisit to Kii ALS-the innovated concept of ALSParkinsonism-dementia complex, clinicopathological features, epidemiology and etiology. Brain Nerve. 2007; 59:1065–74.
   PubMedGoogle Scholar
• Spencer PS, Palmer VS, Ludolph AC. On the decline and etiology of high-incidence motor system disease in West Papua (southwest New Guinea). Mov Disord. 2005; 20Suppl 12:S119–26.
   PubMedGoogle Scholar
• McConnell J. Cyanobacteria, cycads, Chiroptera, and the Chamorro. Lancet Inf Dis. 2004; 4:391–
   PubMedGoogle Scholar
• Rosen DR, Siddique T, Patterson D, . Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993; 362:59–62.
   PubMed Web of Science ®Google Scholar
• Beleza-Meireles A, Al-Chalabi A. Genetic studies of amyotrophic lateral sclerosis: controversies and perspectives. ALS. 2009; 10:1–14.
   Google Scholar
• Mitchell JD. Amyotrophic lateral sclerosis: toxins and environment. Amyotroph Lateral Scler Other Motor Neuron Disord. Sep2000; 14: 235–50.
   PubMed Web of Science ®Google Scholar
• Prasad U. Kurland LT Arrival of new diseases on Guam: lines of evidence suggesting the post-Spanish origins of ALS and Parkinson's dementia. Journal of Pacific History. 1997; 32:217–28.
   Web of Science ®Google Scholar
• Zimmerman HM. quoted in (12)
   Google Scholar
• Kurland LK, Mulder DW. Epidemiologic investigations of amyotrophic lateral sclerosis: I. Preliminary report on geographic distribution, with particular reference to the Mariana Islands, including clinical and pathologic observations. Neurology. 1954; 4:355–378. 338–348.
   PubMed Web of Science ®Google Scholar
• Mulder DW, Kurland LT, Iriarte LL. Neurologic diseases on the island of Guam. US Armed Forces Me J. 1954; 5:1724–39.
   PubMedGoogle Scholar
• Torres J, Iriarte LLG, Kurland LT. Amyotrophic lateral sclerosis among Guamanians in California. Calif Med. 1957; 864: 385–8.
   PubMedGoogle Scholar
• Garruto RM, Gajdusek C, Chen KM. Amyotrophic lateral sclerosis among Chamorro migrants from Guam. Ann Neurol. Dec1980; 86: 612–9.
   PubMed Web of Science ®Google Scholar
• Garruto RM, Gajdusek DC, Chen KM. Amyotrophic lateral sclerosis and parkinsonism-dementia among Filipino migrants to Guam. Ann Neurol. Oct1981; 10 4: 341–50.
   PubMedGoogle Scholar
• Whiting MG1962. Quoted in 86
   Google Scholar
• Mason MM, Whiting MG. Caudal motor weakness and ataxia in cattle in the Caribbean area following ingestion of cycads. Cornell Vet. 1968; 48:541–54.
   PubMedGoogle Scholar
• Reed D, Labarthe D, Chen KM, Stallones R. A cohort study of amyotrophic lateral sclerosis and parkinsonism-dementia on Guam and Rota. Am J Epidemiol. 1987; 1251: 92–100.
   PubMedGoogle Scholar
• Bell EA. Relevance of biochemical taxonomy to the problem of lathyrism. Nature. July 251964; 203:378–380.
   PubMed Web of Science ®Google Scholar
• Vega A, Bell EA. α-Amino-β-methylaminopropionic acid, a new amino acid from seeds of Cycas circinalis. Phytochemistry. 1967; 6:759–62.
   Web of Science ®Google Scholar
• Spencer PS, Schaumburg HH. Lathyrism: a neurotoxic disease. Neurobehav Toxicol Teratol. 1983; 5:625–9.
   PubMedGoogle Scholar
• Spencer PS, Nunn PB, Hugon J, . Motorneurone disease on Guam: possible role of a food neurotoxin. Lancet. 1986a; i:965.
   Google Scholar
• Spencer PS, Roy DN, Ludolph A, . Lathyrism: evidence for role of the neuroexcitatory aminoacid BOAA. Lancet. 1986b; ii:1066–7.
   Google Scholar
• Spencer PS. Guam ALS/parkinsonism-dementia: a long-latency neurotoxic disorder caused by "slow toxin(s)" in food?. Can J Neurol Sci. 1987; 14Suppl 3:347–57.
   PubMedGoogle Scholar
• Spencer PS, Hugon J, Ludolph A, . Discovery and partial characterization of primate motor-system toxins. Ciba Found Symp. 1987; 126:221–38.
   PubMedGoogle Scholar
• Ross SM, Spencer PS. Specific antagonism of behavioral action of "uncommon" amino acids linked to motor-system diseases. Synapse. 1987; 1:248–53.
   PubMed Web of Science ®Google Scholar
• Ross SM, Seelig M, Spencer PS. Specific antagonism of excitotoxic action of ‘uncommon’ amino acids assayed in organotypic mouse cortical cultures. Brain Res. 1987; 425:120–7.
   PubMed Web of Science ®Google Scholar
• Nunn PB, Seelig M, Zagoren JC, . Stereospecific acute neuronotoxicity of “uncommon” plant amino acids linked to human motor-system diseases. Brain Res. 1987; 410:375–9.
   PubMed Web of Science ®Google Scholar
• Spencer PS, Kisby GE, Ludolph AC. Long-latency neurodegenerative disease in the western Pacific. Geriatrics. 1991a; 46Suppl 1:37–42.
   PubMedGoogle Scholar
• Spencer PS, Kisby GE, Ludolph AC. Slow toxins, biologic markers, and long-latency neurodegenerative disease in the western Pacific region. Neurology. 1991b; 41Suppl 2:62–6.
   PubMedGoogle Scholar
• Spencer PS, Allen RG, Kisby GE, Ludolph AC. Exitotoxic disorders. Science. Apr 131990; 248:144.
   PubMed Web of Science ®Google Scholar
• Rubinstein E. Biologic effects of and clinical disorders caused by nonprotein amino acids. Medicine. 2000; 79 2: 80–89.
   PubMedGoogle Scholar
• Duncan MW, Kopin IJ, Garruto RM, . 2-Amino-3(methylamino)-propionic acid in cycad-derived foods is an unlikely cause of amiyotrophic lateral sclerosis/parkinsonism. Lancet. 1988; ii:631–2.
   Google Scholar
• Duncan MW, Steele JC, Kopin IJ, . 2-Amino-3-(methylamino)-propanoic acid (BMAA) in cycad flour:an unlikely cause of amyotrophic lateral sclerosis and parkinsonism-dementia of Guam. Neurology. 1990; 40:767–72.
   PubMed Web of Science ®Google Scholar
• Duncan MW, Villacreses NE, Pearson PG, . 2-amino-3-(methylamino)-propanoic acid (BMAA) pharmacokinetics and blood-brain barrier permeability in the rat. J Pharmacol Exp Ther. 1991; 258:27–35.
   PubMed Web of Science ®Google Scholar
• Smith QR, Nagura H, Takada Y, Duncan MW. Facilitated transport of the neurotoxin, β-N-methylamino-L-alanine, across the blood-brain barrier. J Neurochem. 1992; 58:1330–7.
   PubMed Web of Science ®Google Scholar
• Duncan MW. Beta methylamino-L-alanine (BNAA) and ALS/parkinsonism dementia of the western Pacific. Ann NY Acad Sc. 1992; 648:161–8.
   PubMedGoogle Scholar
• Maurizi CP. Was a neurovirulent influenza virus the cause of amyotrophic lateral sclerosis and parkinsonism-dementia on Guam?. Med Hypotheses. 1987; 23:325–6.
   PubMedGoogle Scholar
• Reed DM, Brody JA. Amyotrophic lateral sclerosis and parkinsonism-dementia on Guam, 1945-1972. I. Descriptive epidemiology. Am J Epidemiol. 1975; 101:287–301.
   PubMed Web of Science ®Google Scholar
• Perl DP, Gajdusek DC, Garruto RM, . Intraneuronal aluminum accumulation in amyotrophic lateral sclerosis and Parkinsonism-dementia of Guam. Science. 1982; 217:1053–5.
   PubMed Web of Science ®Google Scholar
• Perl DP, Moalem S. Aluminum and Alzheimer's disease, a personal perspective after 25 years. J Alzheimers Dis. 2006; 93 Suppl: 291–300.
   PubMed Web of Science ®Google Scholar
• Cox PA, Sacks OW. Cycad neurotoxins, consumption of flying foxes, and ALS-PDC disease in Guam. Neurology. 2002; 58:956–9.
   PubMed Web of Science ®Google Scholar
• Cox PA, Banack SA, Murch SJ. Biomagnification of cyanobacterial neurotoxins and neurodegenerative disease among the Chamorro people of Guam. Proc Natl Acad Sci USA. 2003; 100:13380–3.
   PubMed Web of Science ®Google Scholar
• Banack SA, Cox PA. Biomagnification of cycad neurotoxins in flying foxes: implications for ALS-PDC in Guam. Neurology. 2003; 61:387–9.
   PubMed Web of Science ®Google Scholar
• Murch SJ, Cox PA, Banack SA, Steele JC, Sacks OW. Occurrence of β-methylamino-l-alanine (BMAA) in ALS/PDC patients from Guam. Acta Neurol Scand. 2004a; 110 4: 267–269.
   PubMed Web of Science ®Google Scholar
• Murch SJ, Cox PA, Banack SA. A mechanism for slow release of biomagnified cyanobacterial neurotoxins and neurodegenerative disease in Guam. Proceedings of the National Academy of Sciences. 2004b; 101:12228–31.
   PubMed Web of Science ®Google Scholar
• Banack SA, Murch SJ, Cox PA. Neurotoxic flying foxes as dietary items for the Chamorro people, Marianas Islands. J Ethnopharmacol. 2006; 106:97–104.
   PubMed Web of Science ®Google Scholar
• Banack SA, Johnson HE, Cheng R, Cox PA. Production of the Neurotoxin BMAA by a Marine Cyanobacterium. Mar Drugs. Dec 62007; 5 4: 180–96.
   PubMed Web of Science ®Google Scholar
• Rao SD, Banack SA, Cox PA, . BMAA selectively injures motor neurons via AMPA/kainate receptor activation. Exp Neurol. 2006; 201:244–52.
   PubMed Web of Science ®Google Scholar
• Cox PA, Banack SA, Murch SJ. Cyanobacteria, Cycads, and Neurodegenerative Disease among the Chamorro People of Guam. In: Vovides AP, Stevenson DW, Osborne R. Proceedings of Cycad 2005: The 7th International Conference on Cycad Biology, New york: New york Botanical Garden Press. 2007;253–285.
   Google Scholar
• Allende CC, Allende JE. Purification and substrate specificity of arginyl-ribonucleic acid synthetase from rat liver. J Biol Chem. 1964; 239:1102–1106.
   PubMed Web of Science ®Google Scholar
• Polsky FI, Nunn PB, Bell EA. Distribution and toxicity of α-amino-β-methyl-aminopropionic acid. Fed Proc. 1972; 31:1473–1475.
   PubMedGoogle Scholar
• Rodgers KJ, Shiozawa N. Misincorporation of amino acid analogues into proteins by biosynthesis. Int J Biochem Cell Bio. 2008; 40:1452–1466.
   PubMed Web of Science ®Google Scholar
• Wilhelm SW. Ecology of iron-limited cyanobacteria: a review of physiological responses and implications for aquatic systems. Aquat microbial Ecol. 1995; 9:295–303.
   Web of Science ®Google Scholar
• Usher KM, Bergman B, Raven JA. Exploring cyanobacterial mutualisms. Ann Rev Ecol Evol Systemat. 2007; 38:255–273.
   Google Scholar
• Mash D, Pablo J, Banack SA, . Neurotoxic non-protein amino acid BMAA in brain from patients dying with ALS and Alzheimer's disease. American Academy of Neurology annual meeting. P06.127. Neurology. 2008; 70Suppl 1:A329.
   Google Scholar
• Pablo J, Banack SA, Cox PA, Johnson TE, Papapetropoulos S, Bradley WG, Buck A, Mash DC. Cyanobacterial neurotoxin BMAA in ALS and Alzheimer's disease. Acta Neurol Scand. 2009 Feb 25; DOI: 10.1111/j.1600-0404.2008.01150.x.
   PubMed Web of Science ®Google Scholar
• Mash D, Pablo J, . 2009, paper in preparation.
   Google Scholar
• Valentino KM, Dugger NV, Peterson E, Wilson JM, . Environmentally induced parkinsonism in cycad-fed rats. Society for Neuroscience Abstracts. 2006; : –Poster 755.11/CC19.
   Google Scholar
• Karlsson O, Berg C, Brittebo EB, Lindquist NG. Retention of the cyanobacterial neurotoxin β-N-methylamino-L-alanine in melanin and melanin-containing cells – a possible link between Parkinson-dementia complex and pigmentary retinopathy. Pigment Cell Melanoma Res. 2008; 22:120–30.
   Web of Science ®Google Scholar
• Santucci S, Zsürger N, Chabry J. β-N-methylamino-L-alanine induced in vivo retinal cell death. J Neurochem. 2009; : –10.1111/j.1471-4159.2009.06022.x.
   PubMedGoogle Scholar
• Karlsson O, Lindquist NG, Brittebo EB, Roman E. Selective brain uptake and behavioral effects of the cyanobacterial toxin BMAA following neonatal administration to rodents. Toxicol Sci. 2009; 109:286–295.
   PubMed Web of Science ®Google Scholar
• Cox PA, Banack SA, Murch SJ, . Diverse taxa of cyanobacteria produce ß-N-methylamino-L-alanine, a neurotoxic amino acid. Proc Nat Acad Sci. 2005; 102:5074–78.
   PubMed Web of Science ®Google Scholar
• Garcia-Pichel F, López-Cortés A, Nübel U. Phylogenetic and morphological diversity of cyanobacteria in soil desert crusts from the Colorado plateau. Appl Environ Microbiol. Apr2001; 67 4: 1902–10.
   PubMed Web of Science ®Google Scholar
• Sompong U, Hawkins PR, Besley C, Peerapornpisal Y. The distribution of cyanobacteria across physical and chemical gradients in hot springs in northern Thailand. FEMS Microbiol Ecol. 2005 May 1; 523: 365–76.
   PubMed Web of Science ®Google Scholar
• Walker JJ, Pace NR. Endolithic microbial ecosystems. Annu Rev Microbiol. 2007; 61:331–47.
   PubMed Web of Science ®Google Scholar
• Gorbushina AA. Life on the rocks. Environ Microbiol. Jul2007; 9 7: 1613–31.
   PubMed Web of Science ®Google Scholar
• Johnson HE, King SR, Banack SA, Webster C, Callanaupa WJ, Cox PA. Cyanobacteria (Nostoc commune) used as a dietary item in the Peruvian highlands produce the neurotoxic amino acid BMAA. J Ethnopharmacol. Jun 192008; 118 1: 159–65.
   PubMedGoogle Scholar
• Metcalf JS, Banack SA, Lindsay J, . Co-occurrence of b-N-methylamino-L-alanine, a neurotoxic amino acid, with other cyanobacterial toxins in British waterbodies, 1990–2004. Environmental Microbiology. 2008; 10:702–708.
   PubMed Web of Science ®Google Scholar
• Jonasson S, Eriksson J, Berntzon L, . A novel cyanobacterial toxin (BMAA) with potential neurodegenerative effects. Plant Biotech. 2008; 25:227–32.
   Web of Science ®Google Scholar
• Plato CC, Garruto RM, Galasko D, Craig U-K, . Amyotrophic lateral sclerosis and Parkinson-dementia complex of Guam: changing incidence rates during the past 60 years. Amer J Epidemiol. 2003; 157:149–157.
   PubMed Web of Science ®Google Scholar
• Galasko D, Salmon D, Gamst A, Olichney J. Prevalence of dementia in Chamorros on Guam: relationship to age, gender, education, and APOE. Neurology. 2007 May 22; 6821: 1772–81. Comment: Neurolory. 2007 May 22; 68(21):1759–61.
   PubMedGoogle Scholar
• Monson CS, Banack SA, Cox PA. Conservation implications of Chamorro consumption of flying foxes as a possible cause of ALS-PDC in Guam. Conservation Biol. 2003; 17:678–86.
   Web of Science ®Google Scholar
• Brewer GJ, Terry CA, Aisen AM, Hill GM. Worsening of neurologic syndrome in patients with Wilson's disease with intial penicillamine therapy. Arch Neurol. 1987; 44:490–3.
   PubMed Web of Science ®Google Scholar
• Veen C, van den Hamer CJ, de Leeuw PW. Zinc sulphate therapy for Wilson's disease after acute deterioration during treatment with low-dose D-penicillamine. J Intern Med. 1991; 229:549–552.
   PubMed Web of Science ®Google Scholar
• Lang CJ, Rabas-Kolominsky P, Engelhardt A, Kobras G, Konig HJ. Fatal deterioration of Wilson's disease after institution of oral zinc therapy. Arch Neurol. 1993; 50:1007–8.
   PubMedGoogle Scholar
• Gibberd FB, Billimoria JD, Page NG, Retsas S. Heredopathia atactica polyneuritiformis (Refsum's disease) treated by diet and plasma-exchange. Lancet. 1979; 1 8116: 575–8.
   PubMed Web of Science ®Google Scholar
• Harari D, Gibberd FB, Dick JP, Sidey MC. Plasma exchange in the treatment of Refsum's disease. J Neurol Neurosurg Psychiat. 1991; 54:614–7.
   PubMed Web of Science ®Google Scholar
• Kuzuhara S, Kokubo Y. Atypical parkinsonism of Japan: amyotrophic lateral sclerosis-parkinsonism-dementia complex of the Kii peninsula of Japan (Muro disease): an update. Mov Disord. 2005; Suppl 12: S108–13.
   Google Scholar
• Ince PG, Codd GA. Return of the cycad hypothesis – does the amyotrophic lateral sclerosis/parkinsonism dementia complex (ALS/PDC) of Guam have new implications for global health?Neuropathol Appl Neurobiol. 2005; 31:345–53.
   PubMed Web of Science ®Google Scholar
• Miller G. Guam's Deadly Stalker: On the Loose Worldwide?. Science. 2006; 313:428–431.
   PubMed Web of Science ®Google Scholar
• Papapetropoulos S. Is there a role for naturally occurring cyanobacterial toxins in neurodegeneration? The beta-N-methylamino-L-alanine (BMAA) paradigm. Neurochem Int. 2007; 50:998–1003.
   PubMed Web of Science ®Google Scholar
• Karamyan VT, Speth RC. Animal models of BMAA neurotoxicity: a critical review. Life Sci. 2008; 82:233–46.
   PubMed Web of Science ®Google Scholar
• Rothman SM, Olney JW. Excitotoxicity and the NMDA receptor-still lethal after eight years. Trends Neurosci. 1995; 18:57–8.
   PubMed Web of Science ®Google Scholar
• Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron. 1988; 1:623–34.
   PubMed Web of Science ®Google Scholar
• Yin HZ, Tang DT, Weiss JH. Intrathecal infusion of a Ca2+-permeable AMPA channel blocker slows loss of both motor neurons and of the astrocyte glutamate transporter, GLT-1 in a mutant SOD1 rat model of ALS. Exp Neurol. 2007; 207:177–85.
   PubMed Web of Science ®Google Scholar
• Rothstein JD, Dykes-Hoberg M, Pardo CA, . Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron. 1996; 16:675–86.
   PubMed Web of Science ®Google Scholar
• Trotti D, Rolfs A, Danbolt NC, . SOD1 mutants linked to amyotrophic lateral sclerosis selectively inactivate a glial glutamate transporter. Nat Neurosci. 1999; 2:427–33.
   PubMed Web of Science ®Google Scholar
• Gredal O, Møller SE. Effect of branched-chain amino acids on glutamate metabolism in amyotrophic lateral sclerosis. J Neurol Sci. 1995; 129:40–3.
   PubMedGoogle Scholar
• Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis ALS/Riluzole Study Group. N Engl J Med. 1994; 330:585–91.
   PubMed Web of Science ®Google Scholar
• Weiss JH, Christine CW, Choi DW. Bicarbonate dependence of glutamate receptor activation by ß-N-methylamino-L-alanine. Neuron. 1989a; 3 3: 321–6.
   PubMedGoogle Scholar
• Weiss JH, Koh JY, Choi DW. Neurotoxicity of beta-N-methylamino-L-alanine (BMAA) and beta-N-oxalylamino-L-alanine (BOAA) on cultured cortical neurons. Brain Res. 1989b; 497:64–71.
   PubMed Web of Science ®Google Scholar
• Rakonczay Z, Matsuoka Y, Giacobini E. Effects of L-beta-N-methylamino-L-alanine (L-BMAA) on the cortical cholinergic and glutamatergic systems of the rat. J Neurosci Res. 1991May; 29 1: 121–6.
   PubMedGoogle Scholar
• Matsuoka Y, Rakonczay Z, Giacobini E, Naritoku D. L-beta-methylamino-alanine-induced behavioral changes in rats. Pharmacol Biochem Behav. Mar1993; 443: 727–34.
   PubMed Web of Science ®Google Scholar
• Brownson DM, Mabry TJ, Leslie SW. The cycad neurotoxic amino acid, beta-N-methylamino-L-alanine (BMAA), elevates intracellular calcium levels in dissociated rat brain cells. J Ethnopharmacol. 2002; 82:159–67.
   PubMed Web of Science ®Google Scholar
• Buenz EJ, Howe DL. Beta-methylamino-alanine (BMAA) injures hippocampal neurons in vivo. Neurotoxicology. 2007; 28:702–4.
   PubMed Web of Science ®Google Scholar
• Spencer PS, Nunn PB, Hugon J, . Guam ALS-parkinsonism-dementia linked to a plant excitant neurotoxin. Science. 1987; 237:517–22.
   PubMed Web of Science ®Google Scholar
• Cha JH, Makowiec RL, Penney JB, . L-[3H]-glutamate labels the metabotropic excitatory amino acid receptor in rodent brain. Neurosci Lett. 1990; 113:78–83.
   PubMedGoogle Scholar
• Copani A, Canonico PL, Catania MV, . Interaction between beta-N-methylamino-L-alanine and excitatory amino acid receptors in brain slices and neuronal cultures. Brain Res. 1991; 558:79–86.
   PubMed Web of Science ®Google Scholar
• Staton PC, Bristow DR. The dietary excitotoxins beta-N-methylamino-L-alanine and beta-N-oxalylamino-L-alanine induce necrotic- and apoptotic-like death of rat cerebellar granule cells. J Neurochem. 1997; 69:1508–18.
   PubMedGoogle Scholar
• Nunn PB, Davis AJ, O'Brien P. Carbamate formation and the neurotoxicity of L-alpha amino acids. Science. 1991; 251:1619–20.
   PubMed Web of Science ®Google Scholar
• Pai KS, Shankar SK, Ravindranath V. Billion-fold difference in the toxic potencies of two excitatory plant amino acids, L-BOAA and L-BMAA: biochemical and morphological studies using mouse brain slices. Neurosci Res. 1993; 17 3: 241–8.
   PubMedGoogle Scholar
• Armstrong RA, Lantos PL, Cairns NJ. What determines the molecular composition of abnormal protein aggregates in neurodegenerative disease?Neuropathology. April 23, 2008; 1–15.
   PubMedGoogle Scholar
• Karunakaran S, Saeed U, Ramakrishnan S, Koumar RC, Ravindranath V. Constitutive expression and functional characterization of mitochondrial glutaredoxin (Grx2) in mouse and human brain. Brain Res. 2007. Dec 14; 1185:8–17.
   PubMedGoogle Scholar
• Saeed U, Durgadoss L, Valli RK, Joshi DC, . Knockdown of cytosolic glutaredoxin-1 leads to loss of mitochondrial membrane potential: implication for neurodegenerative diseases. PLoS ONE. 2008; 3 6: e2459–
   Google Scholar
• Lobner D, Piana PM, Salous AK, . Beta-N-methyl-amino-L-alanine enhances neurotoxicity through multiple mechanisms. Neurobiol Dis. 2007; 25:360–6.
   PubMed Web of Science ®Google Scholar
• Liu X, Rush T, Jasmine Z, Lobner D. Beta-N-methyl-amino-L-alanine induces oxidative stress and glutamate release through action on system Xc-. Experimental Neurol. 2009; doi:10.1016/j.expneurol.2009.04.002
   Google Scholar
• Cyanosite at http://www-cyanosite.bio.purdue.edu/index.html (accessed July 14, 2009).
   Google Scholar
• Stewart I, Seawright AA, Shaw GR. Cyanobacterial poisoning in livestock, wild animals and birds – an overview. Adv Exp Med Biol. 2008; 619:613–37.
   PubMed Web of Science ®Google Scholar
• Nunn PB, Ponnusamy M. β-N-Methylaminoalanine (BMAA): Metabolism and metabolic effects in model systems and in neural and other tissues of the rat in vitro. Toxicon. 2009; 54:85–94.
   PubMed Web of Science ®Google Scholar
• Eriksson J, Jonasson S, Papaefthimiou D, Rasmussen U, Bergman B. Improving derivatization efficiency of BMAA utilizing AccQ-Tag® in a complex cyanobacterial matrix. Amino Acids. 2009; 36:43–8.
   PubMed Web of Science ®Google Scholar
• Montine TJ, Li K, Perl DP, . Lack of beta-methylamino-l-alanine in brain from controls, AD, or Chamorros with PDC. Neurology. 2005; 65:768–9.
   PubMed Web of Science ®Google Scholar
• Kisby GE, Roy DN, Spencer PS. Determination of β-N-methylamino-L-alanine (BMAA) in plant (Cycas circinalis L. ) and animal tissue by precolumn derivatization with 9-fluorenylmethyl chloroformate (FMOC) and reversed-phase high-performance liquid chromatography. J Neurosci Methods 1988; 26:45–54.
   Google Scholar
• Kushnir MM, Bergquist J. Beta-methylamino-L-alanine analysis by liquid chromatography tandem mass spectrometry with iTRAQ as the derivative. Eur J Mass Spectrom. 2009; 15 3: 439–43.
   PubMedGoogle Scholar
• Banack SA, Cox PA, Ronnevi L-A. 2009 Unpublished observations
   Google Scholar
• Kubo T, Kato N, Hosoya K, Kaya K. Effective determination method for a cyanobacterial neurotoxin, β-N-methylamino-L-alanine. Toxicon. 2008; 51 7: 1264–8.
   PubMedGoogle Scholar
• Moura S, Ultramari MdA, de Paula DML, Yonamine M, Pinto E. 1H NMR determination of β-N-methylamino-l-alanine (L-BMAA) in environmental and biological samples. Toxicon. 2009; 53 5: 578–83.
   PubMedGoogle Scholar
• Snyder LR, Cruz-Aguado R, Sadilek M, . Lack of cerebral BMAA in human cerebral cortex. Neurology. 2009; 72 15: 1360–1.
   PubMedGoogle Scholar
• Rosén J, Hellenäs KE. Determination of the neurotoxin BMAA (β-N-methylamino-L-alanine) in cycad seed and cyanobacteria by LC-MS/MS (liquid chromatography tandem mass spectrometry). Analyst. 2008; 133 12: 1785–9.
   PubMedGoogle Scholar
• Dietrich DR, Fischer A, Michel C, Hoeger SJ. Toxin mixture in cyanobacterial blooms–a critical comparison of reality with current procedures employed in human health risk assessment. Adv Exp Med Biol. 2008; 619:885–912.
   PubMed Web of Science ®Google Scholar
• Neurotoxin is absent from Cyanotech's spirulina. June 13, 2005 (at http://www.nutraingredients-usa.com/Industry/Neurotoxin-is-absent-from-Cyanotech-s-spirulina, downloaded August 19, 2008).
   Google Scholar
• Cox PA, Banack SA, Murch S, . (22 December 2006) Neurology http://www.neurology.org/cgi/eletters/65/5/768
   Google Scholar
• Steele JC, McGeer PL. The ALS/PDC syndrome of Guam and the cycad hypothesis. Neurology. 2008; 70 21: 1984–90.
   PubMedGoogle Scholar
• Borenstein AR, Mortimer JA, Schellenberg GD, Galasko D. The ALS/PDC syndrome of Guam and the cycad hypothesis. Neurology. 2009; 72:473.
   PubMedGoogle Scholar
• Bradley WG, Banack SA, Cox PA. The ALS/PDC syndrome of Guam and the cycad hypothesis. Neurology. 2009; 2:474.
   Google Scholar
• Cruz-Aguado R, Shaw CA. The ALS/PDC syndrome of Guam and the cycad hypothesis. Neurology. 2009; 72:474.
   PubMedGoogle Scholar
• Spencer PS, Palmer V, Kisby G. The ALS/PDC syndrome of Guam and the cycad hypothesis. Neurology. 2009; 72:474–5.
   PubMed Web of Science ®Google Scholar
• Spina S, Murrell JR, Huey ED, Wassermann EM, Pietrini P, Grafman J, Ghetti B. Corticobasal syndrome associated with A9D progranulin mutation. J Neuropath exp Neurol. 2007; 66:892–900.
   PubMed Web of Science ®Google Scholar
• Brouwers N, Nuytemans K, van der Zee J, Gijselinck I, . Alzheimer and Parkinson diagnoses in progranulin null mutation carriers in an extended founder family. Arch Neurol. 2007; 64:1436–46.
   PubMedGoogle Scholar
• Wider C, Uitti RJ, Wszolek ZK, Fang JY, . Progranulin gene mutation with an unusual clinical and neuropathologic presentation. Mov Disord. 2008; 23 8: 1168–73.
   PubMedGoogle Scholar
• Ueyama H, Kumamoto T, Horinouchi H, Fujimoto S, Aono H, Tsuda T. Clinical heterogeneity in dysferlinopathy. Intern Med. 2002; 41:505–6.
   PubMedGoogle Scholar
• Chiba Y, Shinde A, Kohara N, Akiguchi I, Nakano S, Hayashi YK, Shibasaki H. Two sisters with dysferlinopathy manifesting different clinical phenotypes. Rinsho Shinkeigaku. 2003; 43:188–91.
   PubMedGoogle Scholar
• Vilchez JJ, Gallano P, Gallano E, Lasa A, . Identification of a novel founder mutation in the DYSF gene causing clinical variability in the Spanish population. Arch Neurol. 2005; 62:1256–9.
   PubMedGoogle Scholar
• Majoor-Krakauer D, Ottman R, Johnson WG, Rowland LP. Familial aggregation of amyotrophic lateral sclerosis, dementia, and Parkinson's disease: evidence of shared genetic susceptibility. Neurology. 1994 Oct; 44 10: 1872–7.
   PubMedGoogle Scholar
• Fallis BA, Hardiman O. Aggregation of neurodegenerative diseases in ALS kindreds. ALS. 2009; 10:95–8.
   Google Scholar
• Seawright A, Brown AW, Nolan CC, Cavanagh JB. Selective degeneration of cerebellar cortical neurons caused by cycad neurotoxin, L-ß-methylaminoalanine (BMAA) in rats. Neuropath appl Neurobiol. 1990; 16:153–169.
   PubMed Web of Science ®Google Scholar
• Wilson JM, Khabazian I, Wong MC, Seyedalikhani A, . Behavioral and neurological correlates of ALS-parkinsonism dementia complex in adult mice fed washed cycad flour. Neuromolecular Med. 2002; 1 3: 207–21.
   PubMedGoogle Scholar
• Wilson JM, Khabazian I, Pow DV, Craig UK, . Decrease in glial glutamate transporter variants and excitatory amino acid receptor down-regulation in a murine model of ALS-PDC. Neuromolecular Med. 2003; 3 2: 105–18.
   PubMedGoogle Scholar
• Wilson JM, Petrik MS, Grant SC, Blackband SJ. Examining the interaction of apo E and neurotoxicity on a murine model of ALS-PDC. Can J Physiol Pharmacol. Feb2005; 83 2: 131–41.
   PubMedGoogle Scholar
• Shaw CA, Wilson JM. Analysis of neurological disease in four dimensions: insight from ALS-PDC epidemiology and animal models. Neurosci Biobehav Rev. 2003 Oct; 276: 493–505.
   PubMedGoogle Scholar
• Ly PTT, Singh S, Shaw CA. Novel environmental toxins: steryl glycosides as a potential etiological factor for age-related neurodegenerative diseases. J Neurosci Res. 2007; 85:231–37.
   PubMedGoogle Scholar
• Shaw CA, Höglinger GU. Neurodegenerative diseases: neurotoxins as sufficient etiologic agents?. Neuromolecular Med. 2008; 10 1: 1–9.
   PubMedGoogle Scholar
• Tabata RC, Wilson JM, Ly P, Zwiegers P, . Chronic exposure to dietary sterol glucosides is neurotoxic to motor neurons and induces an ALS-PDC phenotype. Neuromolecular Med. 2008; 101: 24–39.
   PubMedGoogle Scholar
• Cruz-Aguado R, Winkler D, Shaw CA. Lack of behavioral and neuropathological effects of dietary beta-methyamino-L-alanine (BMAA) in mice. Pharmacol Biochem Behav. 2006; 84:294–9.
   PubMed Web of Science ®Google Scholar
• Khabazian I, Bains JS, Williams DE, Cheung J, . Isolation of various forms of sterol beta-D-glucoside from the seed of Cycas circinalis. J Neurochem. 2002; 82:516–28.
   PubMed Web of Science ®Google Scholar
• Schulz JD, Hawkes EL, Shaw CA. Cycad toxins, Helicobacter pylori and parkinsonism: cholesterol glucosides as the common denominator. Med Hypotheses. 2006; 66 6: 1222–1226.
   PubMed Web of Science ®Google Scholar
• Bouic PJB, Etsebeth S, Liebenberg RW, Albrecht CF, . Beta-sitosterol and beta-sitosterol glucoside stimulate human peripheral blood lymphocyte proliferation. Int J Immunopharmac. 1996; 18:693–7000.
   PubMed Web of Science ®Google Scholar
• . Plant Sterols and Sterolins. Alternative Medicine Review 6.2. (April 2001): p203–
   Google Scholar
• Sahelian R. Beta sitosterol supplement. Undated (at http://www.raysahelian.com/sitosterol.html, accessed August 19, 2008).
   Google Scholar
• Dawson R, Marshall EG, Chan KC, Millard WJ, . Neurochemical and Neurobehavioral Effects of Neonatal Administration of β-N-Methylamino-L-Alanine and 3,3′-Iminodipropionitrile. Neurotox Teratol. 1998; 20 2: 181–192.
   PubMedGoogle Scholar
• Zhou X, Papapetropoulos S, Zhai RG. L-BMAA induces neurodegeneration in Drosophila. American Academy of Neurology annual meeting. 2008; 70Suppl 1:A33. p01.110. Neurology;
   Google Scholar
• Purdie EL, Samsudin S, Eddy FB, Codd GA. Effects of the cyanobacterial neurotoxin β-N-methylamino-L-alanine, on the early-life stage development of zebrafish (Danio rerio). Aquatic Toxicol. 2009; doi:10.1016/j.aquatox.2009.02.009.
   PubMedGoogle Scholar
• Scarmeas N, Shih T, Stern Y, Ottman R, Rowland LP. Premorbid weight, body mass, and varsity athletics in ALS. Neurology. 2002 Sep 10; 59 5: 773–5.
   PubMedGoogle Scholar
• Chiò A, Traynor BJ, Swingler R, Mitchell D, . Amyotrophic lateral sclerosis and soccer: a different epidemiological approach strengthen the previous findings. J Neurol Sci. 2008Jun 15; 2691-2: 187–8.
   PubMedGoogle Scholar
• Johnson RT, Bradley WG, Ritz B R, Rocca WA, Shefner JM, Wolfson C. Committee on the Review of the Scientific Literature on Amyotrophic Lateral Sclerosis in Veterans. Institute of Medicine. Washington, DC: National Academies of Science Press, 2006.
   Google Scholar
• Stommel EW. ALS clusters around lakes in New Hampshire. Personal communication. 2007.
   Google Scholar
• Banack SA, Cox PA, Murch SJ. Flying fox consumption and human neurodegenerative disease in Guam. In: Fleming T, Racey P. Island Bats: Ecology Evolution, and Conervation. Chicago: The Univesity of Chicago Press, 2009 (in press).
   Google Scholar
• Morahan JM, Yu B, Trent BJ, Pamphlett R. Genetic susceptibility to environmental toxicants in ALS. Am J Med Genet B Neuropsychiatr Genet. 2007 Oct 5; 1447: 885–90.
   Web of Science ®Google Scholar
• Valdmanis PN, Kabashi E, Dyck A, Hince P, . Association of paraoxonase gene cluster polymorphisms with ALS in France, Quebec and Sweden. Neurology. 2008; 717: 514–520.
   PubMed Web of Science ®Google Scholar